Effect of combined local treatment with zoledronic acid and basic fibroblast growth factor on implant fixation in ovariectomized rats

被引:102
作者
Gao, Ying
Luo, En [1 ]
Hu, Jing
Xue, Jing
Zhu, Songsong
Li, Jihua
机构
[1] Sichuan Univ, State Key Lab Oral Dis, W China Coll Stomatol, Chengdu 610064, Peoples R China
基金
中国国家自然科学基金;
关键词
Bisphosphonates; Zoledronic acid; Basic fibroblast growth factor; Osteoporosis; Implants; HYDROXYAPATITE-COATED IMPLANTS; TOTAL HIP-ARTHROPLASTY; DRUG-DELIVERY SYSTEM; BONE INGROWTH; BISPHOSPHONATE; ALENDRONATE; CANINE; MODEL; OSTEOPOROSIS; TITANIUM;
D O I
10.1016/j.bone.2008.10.054
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
osteoporosis is a skeletal disorder characterized by low bone mass and deterioration of bone microarchitecture resulting in bone fragility, which impairs fixation of the implants. Zoledronic acid (ZOL) is a potential inhibitor of osteoclast-mediated bone resorption and basic fibroblast growth factor (bFGF) is a growth factor that stimulates osteoblast-mediated bone formation, and these drugs could enhance fixation of implants under osteoporotic conditions. In this Study, 40 ovariectomized (OVX) rats were randomly divided into 4 groups (n=10 for each group) and underwent bilateral tibiae implantation using hydroxyapatite (HA)-coated titanium implant: Control group (distilled water immersing before implantation), ZOL group (1 mg/ml of ZOL immersing), bFGF group (20 mu g/ml of bFGF immersing), and ZOL+bFGF group (1 mg/ml of ZOL and 20 mu g/ml of bFGF immersing). At 3 months after implantation, all animal were sacrificed and the tibiae were harvested for histology, micro-CT examinations and biomechanical testing. Bone area and contact, determined by histomorphometric analysis, were 2.7-fold and 1.8-fold in the ZOL-treated implants, 1.9-fold and 1.8-fold in the bFGF-treated implants, 3.6-fold and 2.3-fold in the both-treated implants compared with controls (p<0.01). Such significant effects were further confirmed by microstructure parameters, the bone volume ratio and the percentage osteointegration were significantly increased by ZOL treatment (3.0-fold and 1.8-fold), bFGF treatment (1.2-fold and 1.9-fold) and ZOL+bFGF treatment (3.3-fold and 2.7-fold) (p<0.001), In addition, push-out test showed that the maximum force and the corresponding interfacial shear strength of the implants treated by ZOL, bFGF and ZOL+bFGF was 8.4-fold and 8.6-fold, 3.8-fold and 3.7-fold, 10.8-fold and 10.7-fold of the control levels, respectively (p<0.05). The combined treatment was better than either treatment alone for force, but was not different from ZOL alone for interfacial strength. The significant correlation between biomechanical and micro-CT parameters demonstrates the role of microstructure assessments in predicting mechanical fixation of implants (p<0.01). Our study Suggests that locally applied ZOL or bFGF may improve implant fixation in the ovariectomized rats, and that combined treatment has more beneficial effects on osseointegration, peri-implant bone formation and maximum force than either intervention alone. (C) 2008 Elsevier Inc. All rights reserved.
引用
收藏
页码:225 / 232
页数:8
相关论文
共 37 条
[1]
Effect of glycerol-L-lactide coating polymer on bone ingrowth of bFGF-coated hydroxyapatite implants [J].
Alt, V ;
Pfefferle, HJ ;
Kreuter, J ;
Stahl, JP ;
Pavlidis, T ;
Meyer, C ;
Mockwitz, J ;
Wenisch, S ;
Schnettler, R .
JOURNAL OF CONTROLLED RELEASE, 2004, 99 (01) :103-111
[2]
Topical, single dose bisphosphonate treatment reduced bone resorption in a rat model for prosthetic loosening [J].
Åstrand, J ;
Aspenberg, P .
JOURNAL OF ORTHOPAEDIC RESEARCH, 2004, 22 (02) :244-249
[3]
Local application of rhTGF-β2 enhances peri-implant bone volume and bone-implant contact in a rat model [J].
De Ranieri, A ;
Virdi, AS ;
Kuroda, S ;
Shott, S ;
Leven, RM ;
Hallab, NJ ;
Sumner, DR .
BONE, 2005, 37 (01) :55-62
[4]
Parathyroid hormone 1-34 enhances titanium implant anchorage in low-density trabecular bone:: A correlative micro-computed tomographic and biomechanical analysis [J].
Gabet, Yankel ;
Mueller, Ralph ;
Levy, Jay ;
Dimarchi, Richard ;
Chorev, Michael ;
Bab, Itai ;
Kohavi, David .
BONE, 2006, 39 (02) :276-282
[5]
Biodegradable elastomeric scaffolds with basic fibroblast growth factor release [J].
Guan, Jianjun ;
Stankus, John J. ;
Wagner, William R. .
JOURNAL OF CONTROLLED RELEASE, 2007, 120 (1-2) :70-78
[6]
Development of new drug delivery system for implant bone augmentation using a basic fibroblast growth factor-gelatin hydrogel complex [J].
Hayashi, Kazuhiko ;
Kubo, Takayasu ;
Doi, Kazuya ;
Tabata, Yasuhiko ;
Akagawa, Yasumasa .
DENTAL MATERIALS JOURNAL, 2007, 26 (02) :170-177
[7]
Local alendronate increases fixation of implants inserted with bone compaction: 12-week canine study [J].
Jakobsen, Thomas ;
Kold, Soren ;
Bechtold, Joan. E. ;
Elmengaard, Brian ;
Soballe, Kjeld .
JOURNAL OF ORTHOPAEDIC RESEARCH, 2007, 25 (04) :432-441
[8]
Systemic alendronate treatment improves fixation of press-fit implants: A canine study using nonloaded implants [J].
Jensen, Thomas B. ;
Bechtold, Joan E. ;
Chen, Xinqian ;
Soballe, Kjeld .
JOURNAL OF ORTHOPAEDIC RESEARCH, 2007, 25 (06) :772-778
[9]
The bisphosphonate pamidronate on the surface of titanium stimulates bone formation around tibial implants in rats [J].
Kajiwara, H ;
Yamaza, T ;
Yoshinari, M ;
Goto, T ;
Iyama, S ;
Atsuta, I ;
Kido, MA ;
Tanaka, T .
BIOMATERIALS, 2005, 26 (06) :581-587
[10]
The bisphosphonate ibandronate improves implant integration in osteopenic ovariectomized rats [J].
Kurth, AHA ;
Eberhardt, C ;
Müller, S ;
Steinacker, M ;
Schwarz, M ;
Bauss, F .
BONE, 2005, 37 (02) :204-210